Evidence for the in vivo degradation of human respiratory mucins during Pseudomonas aeruginosa infection

N Houdret, R Ramphal, A Scharfman, JM Perini… - … et Biophysica Acta (BBA …, 1989 - Elsevier
N Houdret, R Ramphal, A Scharfman, JM Perini, M Filliat, G Lamblin, P Roussei
Biochimica et Biophysica Acta (BBA)-General Subjects, 1989Elsevier
The comparison of distribution of glycopeptides of sputa from patients suffering from various
chronic hypersecretions has already shown an increased acidity with a decreased
proportion of neutral glycopeptides in the respiratory secretions of patients suffering from
cystic fibrosis, as compared to those of patients with chronic bronchitis. In order to find out
whether this decrease is specific to cystic fibrosis mucins or whether it is due to a
degradation of mucus by Pseudomonas aeruginosa, which infects most of the sputa from …
Abstract
The comparison of distribution of glycopeptides of sputa from patients suffering from various chronic hypersecretions has already shown an increased acidity with a decreased proportion of neutral glycopeptides in the respiratory secretions of patients suffering from cystic fibrosis, as compared to those of patients with chronic bronchitis. In order to find out whether this decrease is specific to cystic fibrosis mucins or whether it is due to a degradation of mucus by Pseudomonas aeruginosa, which infects most of the sputa from patients with this disease, mucus glycopeptides from patients with different chronic bronchial disorders, infected by Pseudomonas or not, were prepared and fractionated by ion-exchange chromatography. The neutral fraction, which has never been studied in detail, was gel-filtered, and provided two fractions, one containing true mucin glycopeptides and the other containing a mixture of peptides and glycopeptides with a lower molecular mass. In the Pseudomonas-infected samples, the true mucin glycopeptide fraction was greatly diminished as compared to this same fraction in non-Pseudomonas-infected samples; this was not specific to cystic fibrosis secretions. In contrast, the glycopeptide fraction with a lower molecular mass was greatly increased in all the Pseudomonas-infected samples. Polyacrylamide gel electrophoresis of this second fraction showed unique glycopeptide bands between 40–50 kDa in the Pseudomonas-infected samples, regardless of the origin of the samples. These bands were revealed by an antibody directed against whole cystic fibrosis mucin. Infected chronic bronchitis sputa and cystic fibrosis samples without P. aeruginosa did not show these bands. These studies therefore suggest that there are P. aeruginosa-associated changes in mucins which may result from degradation of mucins.
Elsevier